Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Low-molecular-weight carbohydrate Pentaisomaltose may replace dimethyl sulfoxide as a safer cryoprotectant for cryopreservation of peripheral blood stem cells

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Blood group genotyping of blood donors: validation of a highly accurate routine method

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Oral iron supplementation is not associated with short-term risk of infections: results from the Danish Blood Donor Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Frequent blood donation and offspring scholastic attainment: an assessment of long-term consequences of prenatal iron deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Frequent blood donation and offspring birth weight-a next-generation association?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Only minor stem cell mobilization in head and neck irradiated patients treated with hyperbaric oxygen

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Autolog stamcellebehandling til patienter med multipel sklerose

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Cryopreserved hematopoietic stem cell products are widely used for certain hematologic malignancies. Dimethyl sulfoxide (DMSO) is the most widely used cryoprotective agent (CPA) today, but due to indications of cellular toxicity, changes of the cellular epigenetic state, and patient-related side effects, there is an increasing demand for DMSO-free alternatives. We therefore investigated whether Pentaisomaltose (PIM), a low-molecular-weight carbohydrate (1 kDa), can be used for cryopreservation of peripheral blood stem cells, more specifically hematopoietic progenitor cell apheresis (HPC(A)) product.

STUDY DESIGN AND METHODS: We cryopreserved patient or donor HPC(A) products using 10% DMSO or 16% PIM and quantified the recovery of CD34+ cells and CD34+ subpopulations by multicolor flow cytometry. In addition, we compared the frequency of HPCs after DMSO and PIM cryopreservation using the colony-forming cells (CFCs) assay.

RESULTS: The mean CD34+ cell recovery was 56.3 ± 23.7% (11.4%-97.3%) and 58.2 ± 10.0% (45.7%-76.9%) for 10% DMSO and 16% PIM, respectively. The distribution of CD34+ cell subpopulations was similar when comparing DMSO or PIM as CPA. CFC assay showed mean colony numbers of 70.7 ± 25.4 (range, 37.8-115.5) and 67.7 ± 15.7 (range, 48-86) for 10% DMSO and 16% PIM, respectively.

CONCLUSION: Our findings demonstrate that PIM cryopreservation of HPC(A) products provides recovery of CD34+ cells, CD34+ subpopulations, and CFCs similar to that of DMSO cryopreservation and therefore may have the potential to be used for cryopreservation of peripheral blood stem cells.

Original languageEnglish
JournalTransfusion
Volume56
Issue number5
Pages (from-to)1088-95
Number of pages8
ISSN0041-1132
DOIs
Publication statusPublished - May 2016

    Research areas

  • Journal Article

ID: 48989061